Moderna says flu shot misses early success bar, but expects 2024 revenue –
- Moderna says flu shot misses early success bar, but expects 2024 revenue Reuters
- Moderna says there are not enough cases to declare early success for its mRNA flu vaccine CNBC Television
- Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027 CNBC
- Moderna’s mRNA flu shot struggles to prove its worth again in phase 3 trial FierceBiotech
- Why Moderna Stock Is Sliding Despite Positive Vaccines Update Barron’s
- View Full Coverage on Google News
Read More: Moderna says flu shot misses early success bar, but expects 2024 revenue –